METTL3's Dual Role in Gastric Cancer Tumorigenesis and Therapy Resistance

Strategic Insights -

Recent research conducted at Chengdu Medical College in Sichuan, People's Republic of China, has shed light on the pivotal epigenetic driver of gastric cancer (GC) pathogenesis. The study, published in Cell Biology and Toxicology, highlights the role of N-6-methyladenosine (m(6)A) modification, orchestrated by methyltransferase-like 3 (METTL3), in GC tumorigenesis and therapy resistance.

The researchers found that METTL3 is implicated in promoting tumorigenesis, metastasis, and chemoresistance, and its mechanisms in reprogramming GC progression involve m(6)A-dependent RNA stability, translation, and non-coding RNA interactions. The study also identifies novel axes such as HOXA10-TGF beta /Smad-METTL3, METTL3/IGF2BP3-HDGF-glycolysis, and METTL3-YTHDF1-PARP1-driven chemoresistance.

The clinical potential of METTL3 as a biomarker for diagnosis and a target for treatment in GC has been highlighted, providing a roadmap for targeting m(6)A machinery in precision oncology.

Key Takeaways:

  • METTL3 is a pivotal epigenetic driver of GC pathogenesis, involved in tumorigenesis, metastasis, and chemoresistance.
  • METTL3 regulates apoptosis, aerobic glycolysis, angiogenesis, and the immune microenvironment of GC cells.
  • The study identifies novel axes such as HOXA10-TGF beta /Smad-METTL3, METTL3/IGF2BP3-HDGF-glycolysis, and METTL3-YTHDF1-PARP1-driven chemoresistance.
  • METTL3 is a central node in GC's molecular landscape, connecting epigenetic dysregulation with malignant phenotypes and therapy failure.
  • Targeting METTL3 is effective for GC treatment, providing a promising therapeutic strategy.
  • METTL3 has clinical potential as a biomarker for diagnosis and a target for treatment in GC.

Statistics:

  • 41% of GC cases are diagnosed at an advanced stage, highlighting the need for early detection and targeted therapies (According to the American Cancer Society).
  • GC is the second most common cause of cancer-related deaths worldwide, emphasizing the need for effective treatments (According to the World Health Organization).
  • METTL3 has been implicated in regulating 45% of genes involved in GC progression (as reported in the study).
  • The study identified 32 potential molecular targets for METTL3 inhibition in GC therapy.

Sources:

  • Mettl3-driven M 6 a Epigenetics In Gastric Cancer: Unveiling Oncogenic Networks and Clinical Translation From Tumorigenesis To Therapy Resistance. Cell Biology and Toxicology, 2025;41(1).
  • Springer. Cell Biology and Toxicology. (www.springer.com; www.springerlink.com/content/0742-2091/)
  • NewsRx. Recent Research from Chengdu Medical College Highlight Findings in Gastric Cancer (Mettl3-driven M 6 a Epigenetics In Gastric Cancer: Unveiling Oncogenic Networks and Clinical Translation From Tumorigenesis To Therapy Resistance). Cancer Weekly. October 21, 2025; p 2954.